Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Volitionrx Ltd (VNRX)

Volitionrx Ltd (VNRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update PR Newswire - Wed Mar 25, 3:12PM CDT

Conference call to take place on Wednesday, April 1 at 8:30 a.m. U.S Eastern Time

VNRX : 0.1913 (-4.87%)
Volition Announces Detection of Over 95% of Early-Stage Cancers PR Newswire - Wed Mar 25, 7:17AM CDT

HENDERSON, Nev. , March 25, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces compelling proof of concept data from a blinded...

VNRX : 0.1913 (-4.87%)
Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA PR Newswire - Wed Mar 18, 7:17AM CDT

HENDERSON, Nev. , March 18, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is the first to demonstrate the isolation and analysis...

VNRX : 0.1913 (-4.87%)
Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems PR Newswire - Fri Mar 6, 7:10AM CST

HENDERSON, Nev. , March 6, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the completion of all validation and verification...

VNRX : 0.1913 (-4.87%)
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution PR Newswire - Wed Feb 25, 7:10AM CST

HENDERSON, Nev. , Feb. 25, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is pleased to provide a consolidated update on the significant...

VNRX : 0.1913 (-4.87%)
Volition Announces the Appointment of New Distributor for Nu.Q® Discover PR Newswire - Tue Feb 10, 7:07AM CST

HENDERSON, Nev. , Feb. 10, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of Medical & Biological Laboratories...

VNRX : 0.1913 (-4.87%)
VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards PR Newswire - Mon Feb 9, 4:20PM CST

HENDERSON, Nev. , Feb. 9, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that on February 6, 2026,...

VNRX : 0.1913 (-4.87%)
Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation PR Newswire - Wed Feb 4, 7:45AM CST

  Showing New Indication for Nu.Q ® NETs 

VNRX : 0.1913 (-4.87%)
VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays PR Newswire - Fri Jan 30, 7:50AM CST

HENDERSON, Nev. , Jan. 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the preparation of the reimbursement submission...

VNRX : 0.1913 (-4.87%)
Volition Announces Data to Support Use of Nu.Q® NETs in New Indication PR Newswire - Tue Jan 27, 7:00AM CST

Nu.Q® Biomarker Paper Available on MedRXIV

VNRX : 0.1913 (-4.87%)

Barchart Exclusives

EchoStar Stock Just Broke Above Its 50-Day Moving Average on SpaceX IPO Hype. Does That Make SATS a Buy? Barchart - Wed Mar 25, 3:17PM CDT
EchoStar shares soar on reports that SpaceX could file for IPO next week. Here’s why SATS stock remains worth owning in 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.